Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Maze Therapeutics, Inc.NASDAQ: MAZE

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$20M, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was -$20M.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$20M or moves back toward the trailing-twelve-month quarterly average of -$5M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$20M— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$20M— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Accounts receivables amounts to 100.0% of revenue for MAZE, versus a peer median of 6.5%.
MAZE Competitors
Accounts Receivables for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$44.38M USD-720.6%-40.6%4.4%
ARDXArdelyx, Inc.LTM Mar 2026$36.37M USD+98.7%+25.1%8.5%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20M USD——100.0%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$13.84M USD-76.0%+168.7%2.1%
SEPNSepterna, Inc.LTM Sep 2026$10.24M USD+21.4%—10.6%
IVAInventiva S.A.FY2025€816.45K EUR-70.9%-40.3%18.2%
BIOABioAge Labs, Inc.LTM Mar 2026$348K USD-3.6%—3.4%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$49.73K USD-134.1%——
Peer median (excluding MAZE) —-70.9%-7.6%6.5%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(114.94M)(100.42M)52.23M(131.12M)
Depreciation & Amortization3.82M4.09M3.3M2.4M
Deferred Income Tax0000
Stock-Based Compensation6.74M8.75M9.65M16.4M
Change in Working Capital(3.24M)(6.32M)(1.52M)(2.27M)
Accounts Receivables0000
Inventory0000
Accounts Payables(3.78M)399K(204K)(27K)
Other Working Capital541K(6.72M)(1.32M)(2.25M)
Other Non-Cash Items8.42M7.07M12.3M2.65M
Operating Cash Flow(99.2M)(86.83M)75.95M(111.94M)
Capital Expenditures(1.97M)(441K)(1.15M)(794K)
Acquisitions (Net)(1.2M)000
Purchases of Investments000(187.67M)
Sales of Investments00017.5M
Other Investing Activities0000
Investing Cash Flow(3.17M)(441K)(1.15M)(170.96M)
Debt Repayment016.18M24.48M0
Common Stock Issued1.73M209K68.37M275.84M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities000(500K)
Financing Cash Flow1.73M16.39M92.85M275.34M
Effect of Forex Changes0000
Net Change in Cash(100.65M)(70.88M)167.65M(7.57M)
Free Cash Flow(101.17M)(87.27M)74.81M(112.73M)

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.